Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders

Summary

This observational study evaluates functional and developmental outcomes in pediatric participants undergoing a two week intensive multimodal neurorehabilitation program. The program is designed for children with neurodevelopmental disorders, including but not limited to cerebral palsy, autism spectrum disorder, developmental delay, hypoxic ischemic encephalopathy (HIE), and chromosomal or genetic abnormalities.

Participants receive individualized therapy sessions for approximately 2.5 hours per day over a two week period. The intervention is not standardized but is tailored to each child's specific needs and may include components such as sensory integration, motor planning, reflex integration, oculomotor training, executive functioning activities, communication support, and other brain based therapeutic approaches.

The purpose of this study is to observe changes in functional abilities, including attention, motor coordination, emotional regulation, communication, and activities of daily living. Outcomes are assessed using clinician observation and parent reported changes before and after the intensive program, with limited follow-up when available.

This study does not assign participants to a specific treatment as part of a research protocol. Instead, it collects real world data from children already participating in a clinical therapy program to better understand potential benefits of intensive, individualized neurorehabilitation approaches.

Conditions

• Neurodevelopmental Disorders
• Neurodevelopmental Disorders (NDD)
• Neurodevelopmental Disorders and Developmental Abnormalities
• Developmental Delay (Disorder)
• Cerebral Palsy (CP)
• Cerebral Palsy Hemiparetic Cerebral Palsy Spasticity Gait Disorders, Neurologic Postural Balance Impairment
• Cerebral Palsy Infantile
• Cerebral Palsy Spastic Hemiplegic
• Cerebral Palsy, Dyskinetic
• Autism Spectrum Disorder
• Autism Spectrum Disorder (ASD
• Hypoxic Ischemic Encephalopathy
• Hypoxic Ischemic Encephalopathy (HIE)
• Traumatic Brain Injury (TBI)
• Sensory Processing Disorder
• Chromosomal Abnormalities
• Genetic Disorders
• Down Syndrome (Trisomy 21)
• Fragile X Syndrome (FXS)
• RETT Syndrome With Proven MECP2 Mutation
• Williams Syndrome
• 22q11.2 Deletion Syndrome
• Sensorimotor Integration

Sponsors & Collaborators

• Healing Hope International

  lead OTHER

Principal Investigators

• Dr. Tina Casoglos-Adamopoulos, OT, OTD, BCP · Board Certified Pediatric Therapist Executive Director Ability and Beyond Integrated Therapies

Eligibility

Min Age

4 Years

Max Age

12 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-03-01

Primary Completion

2028-01-01

Completion

2036-12-30

Countries

• United States

Study Locations